


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use~~ A method of treating or preventing a disorder in which the blocking of purine receptors is beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (1):



(I)

R₁ is H or NH₂;

R₂ is optionally substituted aryl or heteroaryl attached via a carbon atom;

R₃ is H; optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl, halogen; OH or OR₁₀;

R₄ is H, optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl,

R₅ is H or optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl;

or R₄ and R₅ together form a 5 or 6-membered heterocyclic ring;

R₁₀ is optionally substituted C₁-C₆alkyl;

~~and/or a pharmaceutically acceptable salts and prodrugs salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial, PROVIDED THAT when R₂ is optionally substituted aryl the said use is not the manufacture of a medicament for~~ method is not for the treatment or prevention of inflammatory pain.

2. (Currently Amended) ~~The use~~ method as claimed in claim 1 wherein R₂ is optionally


substituted phenyl.

3. (Currently Amended) The ~~use~~method as claimed in claim 1 wherein R₂ is optionally substituted monocyclic or bicyclic heteroaryl.
4. (Currently Amended) The ~~use~~method as claimed in claim 1 wherein R₂ is optionally substituted furyl, thienyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, indolyl or benzofuranyl.
5. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~claim 1 wherein optional substituents present in R₂ are selected from C₁-C₃ alkyl, C₁-C₃ alkoxy and carboxamide groups.
6. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 4~~claim 1 wherein optional substituents present in R₂ are selected from methyl, ethyl, methoxy, ethoxy, cyano, chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups -CONR^AR^B where R^A and R^B are independently hydrogen, methyl or ethyl.
7. (Currently Amended) The ~~use~~method as claimed in claim 1 wherein R₂ is 2-furyl, 5-methyl-2-furyl, 2-thiazolyl, 4methyl-2-thiazolyl, phenyl, 3-cyano-phenyl, or o-methyl-phenyl.
8. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~claim 1 wherein R₃ is H, C₁-C₆alkyl, C₃-C₆ cycloalkyl, halo substituted C₁-C₆alkyl, or halogen.
9. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 7~~claim 1 wherein R₃ is H, methyl, ethyl, n- or isopropyl, cyclopropyl, no, sec- or tert-butyl, trifloromethyl, chloro, bromo or fluoro.
10. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~claim 1 wherein R₄ is C₁-C₆alkyl, substituted by aryl or heteroaryl, the said aryl or heteroaryl ring being optionally substituted.

11. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 9~~claim 1 wherein R₄ is arylmethyl or heteroarylmethyl, the said aryl or heteroaryl ring being optionally substituted.
12. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~claim 1 wherein R₄ is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl.
13. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 9~~claim 1 wherein R₄ is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, imidazolyl, pyrazolyl, and isoxazolyl.
14. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 10 to 13~~claim 10 wherein optional substituents of R₄ are selected from C₁-C₆ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxy-(C₁-C₃ alkyl), chloro, bromo, fluoro, trifluoromethyl, -NR^AR^B, -CONR^AR^B, -NR^ACOR^B where R^A and R^B are independently hydrogen or C₁-C₃ alkyl or together form an optionally substituted 5 or 6-membered heterocyclic ring.
15. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~claim 1 wherein R₅ is hydrogen.
16. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 9~~claim 1 wherein R₄ and R₆ taken together with the nitrogen to which they are attached form a saturated 5 or 6-membered heterocyclic ring, optionally benzo-fused.
17. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 9~~claim 1 wherein R₄ and R₅ taken together with the nitrogen to which they are attached form a dihydroindolyl, dihydroisoindolyl, tetrahydroquinolyl or tetrahydroisoquinolyl ring system.

18. (Canceled)

19. (Currently Amended) A compound of formula (I) as defined in any of claims 1 to 17,
(I):



R₁ is H or NH₂;

R₂ is optionally substituted aryl or heteroaryl attached via a carbon atom;

R₃ is H; optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl, halogen; OH or OR₁₀;

R₄ is H, optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl,

R₅ is H or optionally substituted C₁-C₆ alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl;

or R₄ and R₅ together form a 5 or 6-membered heterocyclic ring;

R₁₀ is optionally substituted C₁-C₆alkyl;

or a pharmaceutically acceptable salt or prodrug thereof PROVIDED THAT: (a) R₂ is not an optionally substituted pyrazolopyridine ring system; and (b) when R₁ and R₃ are hydrogen and R₂ is unsubstituted phenyl then -NR₄R₅ is not -NH₂, NHCH₃ or N(CH₃)₂; and (c) when R₁ is -NH₂ and R₃ is hydrogen, then R₂ is not phenyl or phenyl substituted by one or more substituents selected from halogen, hydroxy, C₁-C₆ alkyl, C₁C₆ alkoxy, nitro, -NH₂, or -NHCOCH₃.

20. (Original)A compound as claimed in claim 19 wherein R₁ is -NH₂ and R₃ is hydrogen, and R₂ is substituted phenyl, the substituent(s) in the phenyl being selected from, methylenedioxy, C₁-C₆ alkylthio, trifluoromethyl, trifluoromethoxy, nitrile (-CN), oxo, COR^A,

CONHR^A, -CONR^AR^B, -NHR^A, NR^AR^B, -NHCOR^C, -NHCOOR^A, -NR^BCOOR^A wherein R^A and R^B are independently a C₁-C₆ alkyl group and wherein R^C is a C₂-C₆ alkyl group.

21. (Original) A compound as claimed in claim 19 wherein the compound is selected from any of the compounds as shown in Table 1.

22. (Currently Amended) ~~For use in~~ A therapy comprising administering an effective amount of a compound as claimed in any of claims 19 to 21 claim 19.

23. (Currently Amended) A pharmaceutical composition comprising a compound as claimed ~~in any of claims 19 to 21~~ claim 19 in combination with a pharmaceutically acceptable carrier or excipients.

24. (Currently Amended) ~~A use as claimed in any of claims 1 to 17 or a~~ The method as claimed in claim 18 1 wherein said receptors are adenosine receptors.


25. (Currently Amended) ~~A use as claimed in any of claims 1 to 17 or a~~ The method as claimed in claim 18 1 wherein said receptors are adenosine A_{2A} receptors.

26. (Currently Amended) ~~A use as claimed in any of claims 1 to 17 or a~~ The method as claimed in claim 18 1 wherein the disorders are selected from movement disorders; acute and chronic pain other than inflammatory pain; anxiety disorders, affective disorders; central and peripheral nervous system degenerative disorders; schizophrenia; cognitive and memory impairment disorders; attention disorders; central nervous system injury; cerebral ischaemia; myocardial ischaemia; muscle ischaemia; sleep disorders; eye disorders; cardiovascular disorders; and diabetes.

27. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein the movement disorder is selected from Parkinson's disease, progressive supranuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism and spasticity.

28. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 ~~or claim 27~~, wherein the disorder is a movement disorder and the compound of formula (I) is used or administered together with L-DOPA or a dopamine agonist.
29. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein the anxiety disorder is selected from panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.
30. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 ~~or claim 27~~ wherein the disorder is pain.
31. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 ~~or claim 27~~ wherein the disorder is neuropathic pain.
32. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein said affective disorder is selected from bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease.
33. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein said central and peripheral nervous system degenerative disorder is selected from corticobasal degeneration, demyelinating disease, Freidrich's ataxia, motoneurone disease, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy, systemic lupus erythamatosi, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.
34. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein said cognitive and/or memory impairment disorder is selected from dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senife dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome and dementia pugilans.

35. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein attention disorder is selected from attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood and hyperactive child syndrome.
36. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein said central nervous system injury is selected from traumatic brain injury, surgical trauma, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.
37. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein said cerebral ischaemia is transient ischaemic attack, stroke, subarachnoid haemorrhage, cerebral vasospasm, perinatal asphyxia, drowning, cardiac arrest or subdural haematoma.
38. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein the sleep disorder is selected from hypersomnia, narcolepsy and restless legs syndrome.
39. (Currently Amended) ~~A use of~~ The method as claimed in claim 26 wherein the eye disorder is selected from retinal ischaemia-reperfusion injury and diabetic neuropathy.
40. (Canceled)
41. (Currently Amended) A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I):



R₁ is H or NH₂;

R₂ is optionally substituted aryl or heteroaryl attached via a carbon atom;

R₃ is H; optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl, halogen; OH or OR₁₀;

R₄ is H, optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl,

R₅ is H or optionally substituted C₁-C₆ alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl;

or R₄ and R₅ together form a 5 or 6-membered heterocyclic ring;

R₁₀ is optionally substituted C₁-C₆alkyl;

as set out in any of claims 1 to 17 or a pharmaceutically acceptable salt or prodrug thereof.